Drug–Drug Interaction Study of Zanubrutinib With Moderate or Strong CYP3A Inhibitors in Patients With B-Cell Malignancies
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia and Lymphoma
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies
Leukemia and Lymphoma 2022 Dec 08;[EPub Ahead of Print], B Tariq, YC Ou, JC Stern, V Mundra, N Wong Doo, P Walker, KL Lewis, C Lin, W Novotny, S Sahasranaman, S OpatFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.